Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee May Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul SabbatiniJoseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, Mary A. Dwyer

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations

Abstract

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

Original languageEnglish (US)
Pages (from-to)1339-1349
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2012

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Ovarian cancer, version 3.2012: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this